| scholarly article | Q13442814 |
| P2093 | author name string | Alexander Stojadinovic | |
| Itzhak Avital | |||
| Aviram Nissan | |||
| Nathan M Shumway | |||
| George E Peoples | |||
| Kevin P Banks | |||
| Aaron D Kirkpatrick | |||
| Erika J Schneble | |||
| Frederick L Flynt | |||
| Lindsey J Graham | |||
| Matthew P Shupe | |||
| Leonard Henry | |||
| Robert F Setlik | |||
| P2860 | cites work | Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management | Q83801541 |
| Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer | Q86102394 | ||
| Breast awareness: a shift in the paradigm of breast self-examination | Q94947020 | ||
| Mucins in cancer: function, prognosis and therapy | Q24633765 | ||
| Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk | Q28263584 | ||
| Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement | Q28265041 | ||
| Clinical breast examination: practical recommendations for optimizing performance and reporting | Q28292590 | ||
| American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography | Q28295438 | ||
| Breast cancer. Clinical practice guidelines in oncology | Q28308245 | ||
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials | Q29031162 | ||
| Ultrasonographic characteristics of mammographically occult small breast cancer | Q30462327 | ||
| Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. | Q30596473 | ||
| Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases | Q33264119 | ||
| American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer | Q33303529 | ||
| The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? | Q33750000 | ||
| Randomized trial of breast self-examination in Shanghai: final results | Q34152745 | ||
| Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. | Q34220187 | ||
| Options for early breast cancer follow-up in primary and secondary care - a systematic review | Q34303226 | ||
| Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. | Q34468080 | ||
| MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer | Q35088762 | ||
| American Cancer Society guidelines for breast cancer screening: update 2003. | Q35155676 | ||
| Follow-up care of patients treated for breast cancer: a structured review | Q35650439 | ||
| Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. | Q35905932 | ||
| Performance and reporting of clinical breast examination: a review of the literature | Q35945484 | ||
| Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy | Q36106659 | ||
| Diagnostic architectural and dynamic features at breast MR imaging: multicenter study | Q36350990 | ||
| Use of statistics to assess the global burden of breast cancer | Q36375357 | ||
| Alternative methods of follow up in breast cancer: a systematic review of the literature | Q36609505 | ||
| Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience | Q36609609 | ||
| Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature | Q36610756 | ||
| Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review | Q36953121 | ||
| Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer | Q37061904 | ||
| Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis | Q37141797 | ||
| NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis | Q37636597 | ||
| Mammographic surveillance in women with a personal history of breast cancer: how accurate? How effective? | Q37765059 | ||
| Breast MRI screening of women with a personal history of breast cancer | Q37774814 | ||
| Breast cancer screening in women at average risk and high risk | Q37811767 | ||
| A review of breast imaging following mastectomy with or without reconstruction in an outpatient community center | Q37892999 | ||
| Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. | Q38000071 | ||
| Evaluation of appropriate short-term mammographic surveillance in patients who undergo breast-conserving Surgery (BCS). | Q38032790 | ||
| Imaging breast cancer bone metastases: current status and future directions | Q38111023 | ||
| Physical examination. Its role as a single screening modality in the Canadian National Breast Screening Study | Q38792938 | ||
| A minimalist policy for breast cancer surveillance | Q39253380 | ||
| US Preventive Services Task Force. Screening for breast cancer with breast self-examination. A critical review | Q39761981 | ||
| Mammography in patients with breast cancer treated by breast conservation (lumpectomy with or without radiation) | Q40581577 | ||
| The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques | Q43229469 | ||
| Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients. | Q44056799 | ||
| Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers | Q44062079 | ||
| Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up | Q44071678 | ||
| The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan | Q44150197 | ||
| F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging | Q44443422 | ||
| Prognosis following local recurrence in the conservatively treated breast cancer patient | Q45243599 | ||
| A simulation-based assessment of clinical breast examination technique: do patient and clinician factors affect clinician approach? | Q45790506 | ||
| Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer | Q46041652 | ||
| Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer | Q46139570 | ||
| Screening MR imaging versus screening ultrasound: pros and cons | Q46159513 | ||
| Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer | Q46679313 | ||
| Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients | Q46748800 | ||
| Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. | Q46848120 | ||
| F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers | Q46991424 | ||
| Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer | Q47725928 | ||
| American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. | Q50638906 | ||
| An evaluation of post-lumpectomy recurrence rates: is follow-up every 6 months for 2 years needed? | Q51202201 | ||
| 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. | Q51560037 | ||
| Screening for recurrent breast cancer--its effectiveness and prognostic value. | Q52871723 | ||
| The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. | Q53257278 | ||
| Report of the International Workshop on Screening for Breast Cancer. | Q53387874 | ||
| The role of FDG-PET/CT in suspected recurrence of breast cancer. | Q53515121 | ||
| A survey in Puglia: the attitudes and opinions of specialists, general physicians and patients on follow-up practice. G.S.Bio.Ca.M. | Q53651525 | ||
| Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer | Q56020322 | ||
| ACR Appropriateness Criteria Breast Cancer Screening | Q57132506 | ||
| Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators | Q61698715 | ||
| Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: prognostic significance of detection method | Q70761085 | ||
| Preoperative and follow-up procedures on patients with breast cancer | Q71261832 | ||
| It is now the age to define the appropriate follow-up of primary breast cancer patients | Q72182800 | ||
| The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer | Q73259663 | ||
| Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer | Q74390288 | ||
| Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results | Q80165399 | ||
| MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? | Q80605420 | ||
| Is a short-interval postradiation mammogram necessary after conservative surgery and radiation in breast cancer? | Q81068493 | ||
| The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma | Q81525573 | ||
| MR imaging assessment of the breast after breast conservation therapy: distinguishing benign from malignant lesions | Q83212383 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 281-290 | |
| P577 | publication date | 2014-03-16 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | Current approaches and challenges in early detection of breast cancer recurrence | |
| P478 | volume | 5 |
| Q45401326 | A Low-Cost, Low-Skill Model for Efficient Breast Cancer Screening in Low Resource Rural Settings of a Developing Country |
| Q33849708 | A tumor specific antibody to aid breast cancer screening in women with dense breast tissue |
| Q47708739 | Analysis of patient-detected breast cancer recurrence |
| Q37367897 | Clinical surveillance compared with clinical and magnetic resonance imaging surveillance for brain metastasis: a feasibility survey |
| Q37634520 | Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo. |
| Q49419816 | Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality |
| Q61812261 | Overview of the genetic basis toward early detection of breast cancer |
| Q92709891 | Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany |
| Q60920381 | Screening mammography for second breast cancers in women with history of early-stage breast cancer: factors and causes associated with non-detection |
| Q37695246 | Special issue on current challenges and future directions in monitoring recurrence after treatment of primary cancer |
| Q92942918 | The need for rapid therapeutic efficacy testing for cancer therapy |
Search more.